India Exchange Filings

Sai Life Sciences Q2 FY27 Earnings and Board Highlights

Sai Life Sciences Ltd approves unaudited Q2 and H1 FY27 results, with consolidated Q2 revenue of ₹658.6 crore

  • Q2 revenue rose 22.5% year on year and 18.8% sequentially; operating EBITDA margin was 28.9%.
  • Net profit was ₹98.3 crore, up 17.3% year on year and 34.2% sequentially; no exceptional items were reported and the limited-review conclusion was unmodified.
  • Board appointed three senior management personnel and approved allotment of 108,005 shares under employee stock-option plans.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.